Browsing by Author "Ige, O. M."

Filter results by typing the first few letters
Now showing 1 - 2 of 2
  • Thumbnail Image
    Item
    Combination of reduced levels of serum albumin and alpha-2-macroglobulin differentiates newly diagnosed pulmonary tuberculosis patients from patients on chemotherapy
    (2009) Adedapo, K. S.; Arinola, O. G.; Ige, O. M.; Adedapo, A. D. A.
    Pulmonary tuberculosis (PTB) is global disease affecting about one third of the world’s population with its attendant mortality and morbidity. Acute phase proteins have been used in monitoring the progression of infections but not in relation to PTB in this environment. The levels of total protein, albumin, α-2-macroglobulin, transferrin, and haptoglobulin were determined in 23 patients with PTB and 17- age / sex matched PTB-free controls using spectrophotometric and immunodiffusion methods respectively. The result showed that α-2-macroglobulin was significantly raised in PTB patients compared with controls (p<0.001), while the levels of transferrin and albumin were significantly reduced in PTB patients compared with the controls (p<0.001,0.000 respectively). The levels of α-2-macroglobulin and albumin were significantly raised in PTB patients on treatment compared with newly diagnosed PTB patients (p=0.05, p=0.01 respectively). The combination of reduced levels of albumin and α-2-macroglobulin may be used to differentiate newly diagnosed PTB and those on chemotherapy
  • Thumbnail Image
    Item
    Evaluation of modified short course chemotherapy in active pulmonary tuberculosis patients with human immunodeficiency virus infection in University College Hospital, Ibadan, Nigeria- a preliminary report
    (2004) Ige, O. M.; Sogaolu, O. M.; Odaibo, G. N.; Olaleye, O. D.
    Over the period, 1st October 1999 to 30th April 2002 a clinical trail of the modified short-course chemotherapy (SCC) in newly diagnosed cases of pulmonary tuberculosis with human immunodeficiency virus (HIV) infection in Ibdan, Nigeria was carried out. The modified SCC used was adopted by World Health Organisation(WHO)/ International Union against Tuberculosis and Lungs Diseases (IUALTD) for developing countries and also by the Nigerian National Tuberculosis and Leprosy Control Programmed (NTLCP). THe regimen used consisted of ethambutol(E), isoniazid (H), rifampicin (R), and pyrazinamide (Z) in the intensive phase of 2 months. The continuation phase was 6 maonths of ethambutol (E) and isonized (H), i.e. 2EHRZ/6EH. Sputum conversion was 90%at the second month of treatment and therwe was no bacteriological relapse after 18 months of follow-up. Side effects were few and consisted mainly of continuation phase. It is concluded that this modified 8- month chemotherapy regimen adopted by NTLCP is efficacious in treatment of smear positive pulmonary tuberculosis (PTB) patients with background HIV infection.